Top Markets
Coin of the day
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
Rang in Aktien #25836
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Aktienkurs
$0.74834668
Marktkapitalisierung
$45.86M
Veränderung (1 Tag)
-0.15%
Veränderung (1 Jahr)
-6.28%
Land
SE
Handel Mendus AB (publ) (IMMU)

Kategorie

Aktien-Split-Historie für Mendus AB (publ) (IMMU)
Die Aktie Mendus AB (publ) (Symbol: IMMU) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 20, 2026 statt.
Eine IMMU-Aktie, die vor dem Aug 20, 2026 gekauft wurde, entspricht heute 0 IMMU-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
1 x3
AU
0 -
CH
0 -
US